"Our results even show that patients with both conditions who received valve replacement and specific amyloidosis therapy had similar long-term survival rates to people with aortic stenosis without amyloidosis," emphasized study leader Christian Nitsche. This finding is particularly striking because it suggests that the "death sentence" previously associated with the dual diagnosis can be effectively commuted. By addressing both the pressure overload caused by the valve and the infiltrative disease of the muscle, clinicians can return these high-risk patients to a survival curve that mirrors those with much simpler cardiac profiles.
The implications for the aging population are profound. As life expectancy increases globally, the prevalence of both aortic stenosis and cardiac amyloidosis is rising. These are diseases of the "older old," and they frequently mask one another. The symptoms—shortness of breath, fatigue, and reduced exercise tolerance—are common to both, meaning that a clinician who finds a narrowed valve might stop looking further, assuming they have found the sole cause of the patient’s distress.
Targeted tests necessary
The study’s success in improving survival rates has led the research team to issue a call for a shift in diagnostic protocols. Both aortic stenosis and cardiac amyloidosis severely impair the heart’s pumping function, and because they often occur in the same demographic, they can easily be conflated or one can be overlooked. Current estimates suggest that approximately ten percent of patients presenting with severe aortic valve stenosis also harbor underlying cardiac amyloidosis. Despite this high prevalence, the latter is frequently undiagnosed in everyday clinical practice.
The research team argues that the current "standard of care" needs to be updated to reflect the reality of these overlapping pathologies. If a patient undergoes a successful valve replacement but continues to suffer from the progressive stiffening of the heart muscle due to untreated amyloidosis, the clinical outcome remains suboptimal. The study proves that targeted therapy can slow the progression of amyloidosis, while the valve replacement addresses the immediate mechanical stress. Together, they offer a comprehensive shield against the progression of heart failure.
"Our findings also suggest that patients with severe aortic valve stenosis should be screened for amyloidosis so that we can offer them targeted life-prolonging treatment options," emphasized Christian Nitsche. This recommendation points toward a more integrated approach to geriatric cardiology, where imaging techniques such as cardiac MRI or bone scintigraphy—which are highly effective at detecting amyloid deposits—become a more routine part of the workup for patients scheduled for valve interventions.
